SIGNIFICANT ONGOING CLINICAL TRIALS

Definitive, Late Phase Trials

Phase III Treatment Trials in Early Stage Non-Small Cell Lung Cancer Will Assess the Clinical Benefit of Bevacizumab as Part of Adjuvant Therapy and Surgical Resection Techniques

Two definitive phase III studies involving early stage non-small cell lung cancer (NSCLC) were activated in June 2007. ECOG is leading an intergoup trial, E1505, for patients with early stage NSCLC to test if the addition of bevacizumab (angiogenesis inhibition) to standard chemotherapy will improve survival in patients undergoing surgery with curative intent. This study is based on the results of another CTEP-sponsored phase III study in patients with advanced non-squamous NSCLC (E4599) that showed that adding bevacizumab to standard chemotherapy for patients with NSCLC provides a statistically and clinically significant survival advantage with tolerable toxicity.
http://www.clinicaltrials.gov/ct2/show/NCT00324805

The CALGB is conducting a phase III study, CALGB-140503, that will compare two types of surgical resection (standard lobectomy versus sublobar resection) for small (≤ 2 cm) peripheral tumors.
http://www.clinicaltrials.gov/ct2/show/NCT00499330

The results of these two phase III trials may have profound impacts on the management and quality of life of patients with early stage lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006: 355;2542–50.
http://www.ncbi.nlm.nih.gov/pubmed/17167137